Biogen (BIIB) PT Lowered to $275 at BofA Securities
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $209.07 -0.36%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
BofA Securities analyst Geoff Meacham lowered the price target on Biogen (NASDAQ: BIIB) to $275.00 (from $295.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Cullinan Oncology Inc. (CGEM) PT Raised to $27 at UBS
- Citizen Watch (7762:JP) PT Raised to JPY3,000 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
